Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 301–400 of 1,003
Ocio, E. M., Fernández-Lázaro, D., San-Segundo, L., López-Corral, L., Corchete, L. A., Gutiérrez, N. C., Garayoa, M., Paíno, T., García-Gómez, A., Delgado, M., et al. (2015) · Leukemia · doi:10.1038/leu.2014.238 · Cited by 87
A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders
Millrine, D., & Kishimoto, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.006 · Cited by 97
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 98
Self-citationMeganathan, K., Jagtap, S., Wagh, V., Winkler, J., Gaspar, J. A., Hildebrand, D., Trusch, M., Lehmann, K., Hescheler, J., Schlüter, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044228 · Cited by 97
Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases
Vittal, V., Stewart, M. D., Brzovic, P. S., & Klevit, R. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.675165 · Cited by 88
Advancing toxicology research using in vivo high throughput toxicology with small fish models
Planchart, A., Mattingly, C. J., Allen, D., Ceger, P., Casey, W., Hinton, D., Kanungo, J., Kullman, S. W., Tal, T., Bondesson, M., et al. (2016) · ALTEX · doi:10.14573/altex.1601281 · Cited by 96
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library
Powell, C. E., Du, G., Che, J., He, Z., Donovan, K. A., Yue, H., Wang, E. S., Nowak, R. P., Zhang, T., Fischer, E. S., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00520 · Cited by 84
Fionda, C., Abruzzese, M. P., Zingoni, A., Cecere, F., Vulpis, E., Peruzzi, G., Soriani, A., Molfetta, R., Paolini, R., Ricciardi, M. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4603 · Cited by 95
Synthesis and Stability of Oxetane Analogs of Thalidomide and Lenalidomide
Burkhard, J. A., Wuitschik, G., Plancher, J., Rogers‐Evans, M., & Carreira, E. M. (2013) · Organic Letters · doi:10.1021/ol401705a · Cited by 95
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Fedele, P. L., Willis, S. N., Liao, Y., Low, M. S. Y., Rautela, J., Segal, D., Gong, J., Huntington, N. D., Shi, W., Huang, D. C. S., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850727 · Cited by 95
Rui, H., Ashton, K. S., Min, J., Wang, C. W., & Potts, P. R. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00207h · Cited by 94
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · Science Bulletin · doi:10.1016/j.scib.2023.04.028 · Cited by 87
Fecteau, J.-F., Corral, L. G., Ghia, E. M., Gaidarova, S., Futalan, D., Bharati, I. S., Cathers, B. E., Schwaederle, M. C., Cui, B., Lopez‐Girona, A., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559591 · Cited by 93
Dimopoulos, K., Søgaard Helbo, A., Fibiger Munch‐Petersen, H., Sjö, L., Christensen, J., Sommer Kristensen, L., Asmar, F., Hermansen, N. E. U., O'Connel, C., Gimsing, P., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12157 · Cited by 87
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 92
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 92
Affinity-based target identification for bioactive small molecules
Kawatani, M., & Osada, H. (2014) · MedChemComm · doi:10.1039/c3md00276d · Cited by 92
Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage
Suzuki, T., Yamaguchi, H., Kikusato, M., Hashizume, O., Nagatoishi, S., Matsuo, A., Sato, T., Kudo, T., Matsuhashi, T., Murayama, K., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060623 · Cited by 85
Self-citationTranscriptomic and epigenomic characterization of the developing bat wing
Eckalbar, W. L., Schlebusch, S. A., Mason, M. K., Gill, Z., Parker, A. V., Booker, B. M., Nishizaki, S., Muswamba-Nday, C., Terhune, E., Nevonen, K. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3537 · Cited by 79
Schwalm, M. P., & Knapp, S. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102148 · Cited by 91
Zhang, X., Lee, H. C., Shirazi, F., Baladandayuthapani, V., Lin, H., Kuiatse, I., Wang, H., Jones, R. J., Berkova, Z., Singh, R. K., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0044-x · Cited by 81
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2020) · Pharmaceuticals · doi:10.3390/ph13050095 · Cited by 90
Self-citationCereblon covalent modulation through structure-based design of histidine targeting chemical probes
Cruite, J. T., Dann, G. P., Che, J., Donovan, K. A., Ferrao, S., Ficarro, S. B., Fischer, E. S., Gray, N. S., Huerta, F., Kong, N. R., et al. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00078d · Cited by 90
Cross-talk of dioxin and estrogen receptor signals through the ubiquitin system
Ohtake, F., Fujii‐Kuriyama, Y., Kawajiri, K., & Kato, S. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.03.007 · Cited by 90
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18488-4 · Cited by 89
Yamanaka, S., Murai, H., Saito, D., Abe, G., Tokunaga, E., Iwasaki, T., Takahashi, H., Takeda, H., Suzuki, T., Shibata, N., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105375 · Cited by 89
“Recently, humanised-CYP3A mice, but not WT controls, were reported to show modest abnormal limb development in embryo culture, albeit not in vivo , after treatment with thalidomide (Kazuki et al , 2016), suggesting that CYP3A-dependent thalidomide metabolites might induce teratogenesis.”
Self-citationJones, J. R., Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Pawlyn, C., Rasche, L., Melchor, L., Cairns, D. A., Gregory, W. M., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.202200 · Cited by 89
Molecular mechanisms of cereblon-based drugs
Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.004 · Cited by 89
Self-citationYamanaka, S., Horiuchi, Y., Matsuoka, S., Kido, K., Nishino, K., Maeno, M., Shibata, N., Kosako, H., & Sawasaki, T. (2022) · Nature Communications · doi:10.1038/s41467-021-27818-z · Cited by 86
Unveiling the hidden interactome of CRBN molecular glues
Baek, K., Metivier, R. J., Roy Burman, S. S., Bushman, J. W., Yoon, H., Lumpkin, R. J., Ryan, J. K., Abeja, D. M., Lakshminarayan, M., Yue, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62099-w · Cited by 61
Chemical Biology of Natural Products on the Basis of Identification of Target Proteins
Ueda, M. (2012) · Chemistry Letters · doi:10.1246/cl.2012.658 · Cited by 87
BioCreative III interactive task: an overview
Arighi, C. N., Roberts, P. M., Agarwal, S., Bhattacharya, S., Cesareni, G., Chatr-aryamontri, A., Clematide, S., Gaudet, P., Giglio, M. G., Harrow, I., et al. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-s8-s4 · Cited by 82
Discrimination of cytosolic self and non-self RNA by RIG-I-like receptors
Lässig, C., & Hopfner, K.-P. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.788398 · Cited by 76
Del Prete, D., Rice, R. C., Rajadhyaksha, A. M., & D'Adamio, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733626 · Cited by 86
Donoghue, C., Cubillos‐Rojas, M., Gutiérrez, N. M., Sánchez, C., Verdaguer, X., Riéra, A., & Nebreda, Á. R. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112451 · Cited by 86
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 86
Continuous evolution of compact protein degradation tags regulated by selective molecular glues
Mercer, J. A. M., DeCarlo, S. J., Roy Burman, S. S., Sreekanth, V., Nelson, A. T., Hunkeler, M., Chen, P. J., Donovan, K. A., Kokkonda, P., Tiwari, P. K., et al. (2024) · Science · doi:10.1126/science.adk4422 · Cited by 82
Development of inhibitors in the ubiquitination cascade
Zhang, W., & Sidhu, S. S. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.003 · Cited by 86
Targeting chromatin complexes in fusion protein-driven malignancies
Brien, G. L., Stegmaier, K., & Armstrong, S. A. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 86
p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates
Nguyen, T. V., Li, J., Lu, C.-C. (., Mamrosh, J. L., Lu, G., Cathers, B. E., & Deshaies, R. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700949114 · Cited by 85
Yang, K., Zhao, Y., Nie, X., Wu, H., Wang, B., Almodóvar‐Rivera, C. M., Xie, H., & Tang, W. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.04.008 · Cited by 85
Ubiquitin ligases in cancer: Functions and clinical potentials
Duan, S., & Pagano, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.008 · Cited by 85
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
Self-citationThe rise and rise of protein degradation: Opportunities and challenges ahead
Hughes, S. J., Testa, A., Thompson, N., & Churcher, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.006 · Cited by 76
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Yang, W., & Lin, S.-F. (2015) · BioMed Research International · doi:10.1155/2015/341430 · Cited by 84
Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0205-y · Cited by 83
Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4127 · Cited by 83
Thalidomide mimics uridine binding to an aromatic cage in cereblon
Hartmann, M. D., Boichenko, I., Coles, M., Zanini, F., Lupas, A. N., & Hernandez Alvarez, B. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.10.010 · Cited by 83
Target identification of small molecules based on chemical biology approaches
Futamura, Y., Muroi, M., & Osada, H. (2013) · Molecular BioSystems · doi:10.1039/c2mb25468a · Cited by 82
MEIS transcription factors in development and disease
Schulte, D., & Geerts, D. (2019) · Development · doi:10.1242/dev.174706 · Cited by 82
Salinomycin as a potent anticancer stem cell agent: State of the art and future directions
Qi, D., Liu, Y., Li, J., Huang, J. H., Hu, X., & Wu, E. (2021) · Medicinal Research Reviews · doi:10.1002/med.21870 · Cited by 82
Recent advances in isobaric labeling and applications in quantitative proteomics
Sivanich, M. K., Gu, T., Tabang, D. N., & Li, L. (2022) · PROTEOMICS · doi:10.1002/pmic.202100256 · Cited by 82
Hansen, J. D., Condroski, K., Correa, M., Muller, G., Man, H.-W., Ruchelman, A., Zhang, W., Vocanson, F., Crea, T., Liu, W., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01911 · Cited by 75
Examining the evidence for vascular pathogenesis of selected birth defects
Sadler, T. W., & Rasmussen, S. A. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33636 · Cited by 82
Anticancer drug discovery by targeting cullin neddylation
Yu, Q., Jiang, Y., & Sun, Y. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.005 · Cited by 81
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tamura, T., Kawano, M., & Hamachi, I. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00745 · Cited by 81
Chimote, G., Sreenivasan, J., Pawar, N., Subramanian, J., Sharma, S., & Sivaramakrishnan, H. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s55621 · Cited by 81
Chou, T.-F., & Deshaies, R. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215319 · Cited by 64
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma
Chang, X.-B., Zhu, Y., Shi, C., & Stewart, A. K. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt142 · Cited by 80
Redox stress and signaling during vertebrate embryonic development: Regulation and responses
Timme‐Laragy, A. R., Hahn, M. E., Hansen, J. M., Rastogi, A., & Roy, M. A. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.09.019 · Cited by 80
Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction
Qiu, X., Sun, N., Kong, Y., Li, Y., Yang, X., & Jiang, B. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01326 · Cited by 80
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin, E., Bak, S. H., Park, T., Kim, J.-W., Yoon, S. R., Jung, H., & Noh, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192907 · Cited by 79
Nanomaterials for Biosensors and Implantable Biodevices
Luz, R. A. S., Iost, R. M., & Crespilho, F. N. (2012) · Springer eBooks · doi:10.1007/978-3-642-29250-7_2 · Cited by 79
Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
Gemechu, Y., Millrine, D., Hashimoto, S., Prakash, J., Sanchenkova, K., Metwally, H., Gyanu, P., Kang, S., & Kishimoto, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814446115 · Cited by 78
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, K. M., Straube, R., Reitsma, J. M., Sweredoski, M. J., Rose, C. M., Moradian, A., den Besten, W., Hinkle, T., Verschueren, E., Petzold, G., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.013 · Cited by 78
Schafer, P. H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M., & Chopra, R. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212916 · Cited by 78
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
Huth, S. W., Oakley, J. V., Seath, C. P., Geri, J. B., Trowbridge, A., Parker, D. L., Rodriguez‐Rivera, F. P., Schwaid, A. G., Ramil, C. P., Ryu, K. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03325 · Cited by 78
Induced protein degradation for therapeutics: past, present, and future
Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175265 · Cited by 67
Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease
Lee, J., & Zhou, P. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00021 · Cited by 73
Targeting HECT ‐type E3 ligases – insights from catalysis, regulation and inhibitors
Fajner, V., Maspero, E., & Polo, S. (2017) · FEBS Letters · doi:10.1002/1873-3468.12775 · Cited by 78
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77
Lee, K. M., Yang, S.-J., Kim, Y. D., Choi, Y. D., Nam, J. H., Choi, C. S., Choi, H.-S., & Park, C.-S. (2013) · Diabetes · doi:10.2337/db12-1030 · Cited by 77
“Later, CRBN was identified as a primary target for thalidomideinduced teratogenicity and as a substrate receptor for the E3 ligase complex (3).”
BackgroundHan, X., Zhao, L., Xiang, W., Miao, B., Qin, C., Wang, M., Xu, T., McEachern, D., Lü, J., Wang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00405 · Cited by 77
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro
Mahony, C., Erskine, L., Niven, J., Greig, N. H., Figg, W. D., & Vargesson, N. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307684110 · Cited by 69
Coleman, K. G., & Crews, C. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 66
Inducing protein-protein interactions with molecular glues
Che, Y., Gilbert, A. M., Shanmugasundaram, V., & Noe, M. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.046 · Cited by 70
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Pei, H., Peng, Y., Zhao, Q., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra03423d · Cited by 76
Bricelj, A., Ng, Y. L. D., Ferber, D., Kuchta, R. D., Müller, S., Monschke, M., Wagner, K. G., Krönke, J., Sosič, I., Gütschow, M., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00368 · Cited by 75
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022) · Molecules · doi:10.3390/molecules27248828 · Cited by 75
Boise, L., Kaufman, J. L., Bahlis, N. J., Lonial, S., & Lee, K. P. (2014) · Blood · doi:10.1182/blood-2014-05-578732 · Cited by 75
Thalidomide Embryopathy: An Enigmatic Challenge
Vargesson, N. (2013) · ISRN Developmental Biology · doi:10.1155/2013/241016 · Cited by 62
Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance
Sahu, R. K., Yadav, R., Prasad, P., Roy, A., & Chandrakar, S. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-695 · Cited by 75
Thalidomide and its analogues in the treatment of Multiple Myeloma
Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 75
Shi, Q., & Chen, L. (2017) · Journal of Immunology Research · doi:10.1155/2017/9130608 · Cited by 75
BET Bromodomain as a Target of Epigenetic Therapy
Noguchi‐Yachide, T. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00225 · Cited by 74
Chemical Ligand Space of Cereblon
Boichenko, I., Bär, K., Deiss, S., Heim, C., Albrecht, R., Lupas, A. N., Alvarez, B. H., & Hartmann, M. D. (2018) · ACS Omega · doi:10.1021/acsomega.8b00959 · Cited by 74
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73
Han, B. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014715 · Cited by 71
Drug Target Identification in Tissues by Thermal Proteome Profiling
Mateus, A., Kurzawa, N., Perrin, J., Bergamini, G., & Savitski, M. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-013205 · Cited by 73
Opportunities and challenges of protein-based targeted protein degradation
Shen, F., & Dassama, L. M. K. (2023) · Chemical Science · doi:10.1039/d3sc02361c · Cited by 73
Rational Screening for Cooperativity in Small-Molecule Inducers of Protein–Protein Associations
Liu, S., Tong, B., Mason, J. W., Ostrem, J. M., Tutter, A., Hua, B. K., Tang, S. A., Bonazzi, S., Briner, K., Berst, F., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08307 · Cited by 69
Drug safety testing paradigm, current progress and future challenges: an overview
Ahuja, V., & Sharma, S. C. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2935 · Cited by 73
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood · doi:10.1182/blood.2019002395 · Cited by 72
“Pyrexia 37 (38) 1 (1) 11 (44) 0 18 (46) 0 4 (22) 1 (6)”
InfluentialTerahertz Circular Dichroism Spectroscopy of Molecular Assemblies and Nanostructures
Choi, W. J., Lee, S. H., Park, B. C., & Kotov, N. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04817 · Cited by 72
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 73
Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 71
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.